Clinical Trial: Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Prospective, Randomized, Open-Labeled, Active-Controlled Comparison of Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess: A Pilot Study
Brief Summary: This clinical trial compares the use of moxifloxacin versus ceftriaxone in the treatment of primary pyogenic liver abscess. The trial will include nonpregnant adults presenting with primary liver abscess based on clinical diagnosis and computed tomography. The trial aims to determine whether the use of moxifloxacin can effectively treat primary pyogenic liver abscess and shorten hospitalization. This regimen has the additional benefit of avoiding nephrotoxic agents, such as aminoglycosides, used frequently in treatment of pyogenic liver abscess. Development of antibiotic resistance to colonized bacteria in the gastrointestinal tract will also be evaluated using stool cultures.
Detailed Summary:
Sponsor: Kaohsiung Veterans General Hospital.
Current Primary Outcome: Treatment efficacy [ Time Frame: 21 days ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Clinical response [ Time Frame: Day 3, 7 and 14 ]
- Clinical and radiological response [ Time Frame: 21 days ]
- All cause mortality [ Time Frame: 21 days ]
- Mortality attributable to liver abscess during treatment [ Time Frame: 21 days ]
- Rates of complication (metastatic infections to the central nervous system and/or eyes) [ Time Frame: 21 days ]
- Rates of gastrointestinal colonization of Klebsiella pneumoniae in patients and rates of resistance post-antibiotic use. [ Time Frame: 3 months ]
Original Secondary Outcome: Same as current
Information By: Kaohsiung Veterans General Hospital.
Dates:
Date Received: May 6, 2009
Date Started: May 2009
Date Completion:
Last Updated: December 1, 2015
Last Verified: December 2015
